Trial · NCT04117698
Multicenter, Randomized Study Evaluating the Value of Antitubercular Treatment During Recurent Anterior Uveitis (URBA)
NCT04117698, Phase 3, Unknown, Assistance Publique - Hôpitaux de Paris
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Multicenter, Randomized Study Evaluating the Value of Antitubercular Treatment During Recurent Anterior Uveitis (URBA). Trials, record NCT04117698. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04117698
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Multicenter, Randomized Study Evaluating the Value of Antitubercular Treatment During Recurent Anterior Uveitis (URBA)
- NCT number
- NCT04117698
- Status
- Unknown
- Phases
- Phase 3
- Enrollment
- 116 participants, estimated
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Conditions
- Uveitis, Anterior
- Interventions
- Antitubercular treatment (RIFATER ©), Ethambutol, RIFINAH ©
- First posted
- 2019-10-07
- Last updated
- 2019-10-07
Source ClinicalTrials.gov
Registered outcomes46
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Success | at 18 months | Success is defined by uveitis recovery at 3 months and the absence of recurrence at 18 months of follow-up. The intensity of the ocular inflammation will be evaluated using the Standardization of Uveitis Nomenclature (SUN) classification (score of cellular Tyndall and "Flare" of the aqueous humor) Failure is therefore defined as failure to recovery at 3 months of anterior uveitis or recurrence at 18 months. |
| Secondary | Proportion of patients having developped neutropenia | at 6 months | Neutropenia will be defined as PNN less than 1000 mm3 |
| Secondary | Proportion of patients having developped hepatitis with clinical signs | at 6 months | Hepatitis will be defined as hepatitis with clinical signs and ALT greater than 3 times the normal value |
| Secondary | Proportion of patients having developped severe hepatitis | at 6 months | Severe hepatitis will be defined will be defined as ALT greater than 5 times the normal value |
| Secondary | Proportion of patients having developped moderate or severe skin allergy | at 6 months | |
| Secondary | Proportion of patients having developped neuritis or optic atrophy | at 6 months | |
| Secondary | Proportion of patients having developped acute renal failure | at 6 months | |
| Secondary | Proportion of patients having developped peripheral neuropathy | at 6 months | |
| Secondary | Proportion of patients having developped other adverse effects | at 6 months | |
| Secondary | Proportion of patients with recurrence | between 3 months and 18 months |
1 to 10 of 46Source ClinicalTrials.gov
See all 46 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04117698
GET https://conductscience.org/api/trials/v1/NCT04117698/registered?page=2